- 1 Summary
- 2 Legal status
- 3 FAQ
- 3.1 1. What is 1cP-LSD?
- 3.2 2. Is 1cP-LSD legal?
- 3.3 3. What are the effects of 1cP-LSD?
- 3.4 4. How is 1cP-LSD typically consumed?
- 3.5 5. What are the potential risks and side effects of 1cP-LSD?
- 3.6 6. Can 1cP-LSD be detected in drug tests?
- 3.7 7. Is 1cP-LSD safe to use?
- 3.8 8. Can I use 1cP-LSD for therapeutic purposes?
- 3.9 9. Where can I get 1cP-LSD?
- 3.10 10. Is 1cP-LSD addictive?
- 4 References
1cP-LSD, also known as N1-(cyclopropylmethanoyl)-lysergic acid diethylamide, is a lysergic acid diethylamide (LSD) derivative marketed as a designer drug. In mouse experiments, it exhibited notable psychedelic effects, demonstrating potency similar to that of 1P-LSD.
|Chemical and physical data|
|Molar mass||391.515 g·mol−1|
On December 18, 2019, Sweden’s public health agency recommended categorizing 1cP-LSD as a hazardous substance, and subsequently, on April 22, 2021, officially designated it as such.
1. What is 1cP-LSD?
- 1cP-LSD, short for 1-cyclopropyl lysergic acid diethylamide, is a chemical compound and derivative of LSD (lysergic acid diethylamide). It is known for its psychoactive properties and is often categorized as a research chemical or designer drug.
2. Is 1cP-LSD legal?
- The legal status of 1cP-LSD varies from country to country. In some places, it may be considered a controlled substance or fall under analog laws, while in others, it may not be explicitly regulated. It’s crucial to check your local laws and regulations regarding the possession, sale, or use of 1cP-LSD.
3. What are the effects of 1cP-LSD?
- Like LSD, 1cP-LSD is believed to induce psychedelic effects, such as alterations in perception, mood, and consciousness. Users may experience visual distortions, heightened sensory perception, and changes in thought patterns. The intensity and duration of these effects can vary.
4. How is 1cP-LSD typically consumed?
- 1cP-LSD is commonly ingested orally as blotter paper or liquid solution. The substance can also be administered through other routes, but caution is essential due to its potent nature.
5. What are the potential risks and side effects of 1cP-LSD?
- The use of 1cP-LSD carries inherent risks, including the possibility of experiencing anxiety, paranoia, hallucinations, or other adverse psychological effects. Additionally, the substance’s long-term effects and safety profile are not well-studied, so using it involves uncertainties.
6. Can 1cP-LSD be detected in drug tests?
- Standard drug tests typically do not screen for 1cP-LSD precisely. However, some tests might detect its presence as an LSD analog. Always be aware of the testing procedures used in your specific situation.
7. Is 1cP-LSD safe to use?
- The safety of 1cP-LSD is a subject of ongoing research, and conclusive data may be limited. Due to its psychoactive nature, it is essential to approach 1cP-LSD cautiously, use harm reduction practices, and be aware of potential risks.
8. Can I use 1cP-LSD for therapeutic purposes?
- There is no established medical or therapeutic use for 1cP-LSD. LSD and its derivatives have shown some potential in research for various psychological conditions, but self-administration for medicinal purposes is not recommended.
9. Where can I get 1cP-LSD?
- The availability of 1cP-LSD can vary widely depending on your location and local regulations. It may be obtained online from research chemical suppliers in some areas, but sourcing and using it should be done cautiously and in compliance with the law.
10. Is 1cP-LSD addictive?
– There is limited research on the addictive potential of 1cP-LSD. However, it is generally believed to have a low potential for physical dependence. Psychological dependence can occur with frequent use, as with many psychoactive substances.
- Tanaka R, Kawamura M, Hakamatsuka T, Kikura-Hanajiri R (2020). “Identification of LSD Derivatives, including 1cP-LSD, MIPLA, and 1B-LSD, within Illicit Products in the Form of Paper Sheets.” Yakugaku Zasshi. 140 (11): 1405–1413. doi:10.1248/yakushi.20-00124. PMID 33132277.
- Vincenti F, Gregori A, Flammini M, Di Rosa F, Salomone A (July 2021). “Seizures of New Psychoactive Substances on the Italian Territory during the COVID-19 Pandemic.” Forensic Science International. 326: 110904. doi:10.1016/j.forsciint.2021.110904. PMC 8411784. PMID 34371393.
- Brandt SD, Kavanagh PV, Westphal F, Stratford A, Odland AU, Klein AK, et al. (June 2020). “Return of the Lysergamides. Part VI: Analytical and Behavioral Characterization of 1-Cyclopropanoyl-d-Lysergic Acid Diethylamide (1CP-LSD).” Drug Testing and Analysis. 12 (6): 812–826. doi:10.1002/dta.2789. PMC 9191646. PMID 32180350.
- “Förordning (1999:58) om förbud mot vissa hälsofarliga varor” [Regulation (1999:58) on the Prohibition of Certain Hazardous Substances].
- “Tjugotre ämnen föreslås klassas som narkotika eller hälsofarlig vara” [Twenty-three Substances Proposed for Classification as Narcotic or Hazardous Goods] (in Swedish). Folkhälsomyndigheten. December 18, 2019. Archived from the original on November 24, 2022. Retrieved May 28, 2020.